Research and Clinical Trials

Title  

BMS CA209358: Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab and Nivolumab plus Ipilimumab in Subjects with Virus-Positive and Virus-Negative Solid Tumors

Brief Description  

In the neoadjuvant cohort, to investigate the safety and tolerability of neoadjuvant nivolumab administration in the following tumor types: HPV-positive (SCCHN), HPV-negative (SCCHN), Merkel Cell Carcinoma, Cervical, vaginal, or vulvar cancers. In the metastatic/recurrent cohort, to evaluate the investigator-assessed objective response rate (ORR) of nivolumab monotherapy and combination therapy of Nivolumab and Ipilimumab in subjects with the following diseases: Metastatic or recurrent nasophary

Who may be Eligible  

Please contact us for eligibility criteria.

Speciality/Disorder  

Other Skin

Status  

OPEN

Start Date  

01/24/2016

IRB Number  

00014392

Principal Investigator  

Amin, Asim

Contact Name  

Donna Acampora

For More Information, Contact  Donna  , Acampora
Phone:  980-442-2319 Fax:    
Email:  Donna.Acampora@atriumhealth.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204